| Tumor regression in cancer patients by very low doses of a T cell–engaging antibody R Bargou, E Leo, G Zugmaier, M Klinger, M Goebeler, S Knop, ... Science 321 (5891), 974-977, 2008 | 1299 | 2008 |
| Targeted therapy with the T-cell–engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results … MS Topp, P Kufer, N Gökbuget, M Goebeler, M Klinger, S Neumann, ... Journal of clinical oncology 29 (18), 2493-2498, 2011 | 1075 | 2011 |
| Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL MS Topp, N Gökbuget, G Zugmaier, E Degenhard, ME Goebeler, ... Blood, The Journal of the American Society of Hematology 120 (26), 5185-5187, 2012 | 556 | 2012 |
| Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab M Klinger, C Brandl, G Zugmaier, Y Hijazi, RC Bargou, MS Topp, ... Blood, The Journal of the American Society of Hematology 119 (26), 6226-6233, 2012 | 553 | 2012 |
| Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy … W Fischbach, ME Goebeler-Kolve, B Dragosics, A Greiner, M Stolte Gut 53 (1), 34-37, 2004 | 474 | 2004 |
| Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study ME Goebeler, S Knop, A Viardot, P Kufer, MS Topp, H Einsele, ... Journal of Clinical Oncology 34 (10), 1104-1111, 2016 | 468 | 2016 |
| Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma A Viardot, ME Goebeler, G Hess, S Neumann, M Pfreundschuh, N Adrian, ... Blood, The Journal of the American Society of Hematology 127 (11), 1410-1416, 2016 | 390 | 2016 |
| Primary gastric B-cell lymphoma: results of a prospective multicenter study W Fischbach, B Dragosics, ME Kolve–Goebeler, C Ohmann, A Greiner, ... Gastroenterology 119 (5), 1191-1202, 2000 | 321 | 2000 |
| Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking F Braig, A Brandt, M Goebeler, HP Tony, AK Kurze, P Nollau, T Bumm, ... Blood, The Journal of the American Society of Hematology 129 (1), 100-104, 2017 | 262 | 2017 |
| Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia R Hehlmann, U Berger, M Pfirrmann, H Heimpel, A Hochhaus, J Hasford, ... Blood, The Journal of the American Society of Hematology 109 (11), 4686-4692, 2007 | 221 | 2007 |
| Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait … W Fischbach, ME Goebeler, A Ruskone-Fourmestraux, T Wündisch, ... Gut 56 (12), 1685-1687, 2007 | 213 | 2007 |
| A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors M Kebenko, ME Goebeler, M Wolf, A Hasenburg, R Seggewiss-Bernhardt, ... Oncoimmunology 7 (8), e1450710, 2018 | 173 | 2018 |
| Tumor-promoting versus tumor-antagonizing roles of γδ T cells in cancer immunotherapy: results from a prospective phase I/II trial V Kunzmann, M Smetak, B Kimmel, K Weigang-Koehler, M Goebeler, ... Journal of immunotherapy 35 (2), 205-213, 2012 | 169 | 2012 |
| Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group MA Bergmann, ME Goebeler, M Herold, B Emmerich, M Wilhelm, C Ruelfs, ... haematologica 90 (10), 1357-1364, 2005 | 164 | 2005 |
| Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy ME Goebeler, R Bargou Leukemia & lymphoma 57 (5), 1021-1032, 2016 | 156 | 2016 |
| Poor efficacy and tolerability of R‐CHOP in relapsed/refractory chronic lymphocytic leukemia and R ichter transformation P Langerbeins, R Busch, N Anheier, J Dürig, M Bergmann, ME Goebeler, ... American journal of hematology 89 (12), E239-E243, 2014 | 125 | 2014 |
| Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML C Schütz, S Inselmann, S Sausslele, CT Dietz, MC Müller, E Eigendorff, ... Leukemia 31 (4), 829-836, 2017 | 108 | 2017 |
| Diagnostic accuracy of EUS in the local staging of primary gastric lymphoma: results of a prospective, multicenter study comparing EUS with histopathologic stage W Fischbach, ME Goebeler-Kolve, A Greiner Gastrointestinal endoscopy 56 (5), 696-700, 2002 | 99 | 2002 |
| Minimal residual low-grade gastric MALT-type lymphoma after eradication of Helicobacter pylori W Fischbach, M Goebeler-Kolve, P Starostik, A Greiner, ... The Lancet 360 (9332), 547-548, 2002 | 95 | 2002 |
| Association study of a functional Toll-like receptor 4 polymorphism with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma S Hellmig, W Fischbach, ME Goebeler-Kolve, UR Fölsch, J Hampe, ... Leukemia & lymphoma 46 (6), 869-872, 2005 | 92 | 2005 |
